Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 9;5(1):7-23.
doi: 10.1002/ags3.12379. eCollection 2021 Jan.

Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma

Keinosuke Ishido  1 , Kenichi Hakamada  1 , Norihisa Kimura  1 , Takuya Miura  1 , Taiichi Wakiya  1
Affiliations
Review

Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma

Keinosuke Ishido et al. Ann Gastroenterol Surg. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant. While cancers in other organs have shown clear improvements in 5-year survival, the 5-year survival rate of pancreatic cancer is approximately 10%. Early relapse and metastasis are not uncommon, making it difficult to achieve an acceptable prognosis even after complete surgical resection of the pancreas. Studies have been performed on various treatments to improve the prognosis of PDAC, and multidisciplinary approaches including non-surgical treatments have led to gradual improvement. In the present literature review, we have described the significance of anatomical and biological resectability criteria, the concept of R0 resection in surgical treatment, the feasibility of minimally invasive surgery, the remarkable development of perioperative chemotherapy, the effectiveness of conversion surgery for unresectable PDAC, and ongoing challenges in PDAC treatment. We also provide an essential update on these subjects by focusing on recent trends and topics.

Keywords: CA19‐9; conversion surgery; minimally invasive pancreatectomy; neoadjuvant treatment; resectability criteria.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest for this article.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. - PubMed
    1. Luo G, Zhang Y, Guo PI, Ji H, Xiao Y, Li KE, et al. Global patterns and trends in pancreatic cancer incidence: age, period, and birth cohort analysis. Pancreas. 2019;48(2):199–208. - PubMed
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. - PubMed
    1. Shin SH, Kim SC, Song K‐B, Hwang DW, Lee JH, Park K‐M, et al. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single‐center experience with 2,029 patients. Surgery. 2018;164(3):432–42. - PubMed
    1. Bae JS, Kim JH, Joo I, Chang W, Han JK. MDCT findings predicting post‐operative residual tumor and survival in patients with pancreatic cancer. Eur Radiol. 2019;29(7):3714–24. - PubMed